Onvansertib Receives FDA Fast Track Designation in RAS-Mutated Colorectal Cancer

Onvansertib Receives FDA Fast Track Designation in RAS-Mutated Colorectal Cancer

Cardiff Oncology announced on November 16, 2026, that the FDA granted Fast Track designation to onvansertib with FOLFIRI and bevacizumab for first-line treatment of adults with KRAS- or NRAS-mutated metastatic colorectal cancer. The decision follows findings from the randomized phase 2 CRDF-004 trial, as the company prepares for a registrational study.

The development brings attention to a treatment strategy that targets polo-like kinase 1 (PLK1), a protein involved in cell division, to potentially improve the activity of chemotherapy in RAS-mutated disease.

Onvansertib Trial Reports a 72.2% Response Rate

According to Cardiff Oncology’s announcement, the selected regimen, 30 mg onvansertib plus FOLFIRI and bevacizumab, produced a confirmed objective response rate of 72.2%, compared with 42.1% for FOLFIRI and bevacizumab alone, an absolute difference of 30.1 percentage points.

At the September 28, 2026 cutoff, median progression-free survival had not been reached in the 30 mg arm, versus approximately 11 months across the combined standard-of-care arms. These ongoing results remain preliminary.

Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology, said:

“Our randomized Phase 2 data give us confidence that onvansertib may provide an additive benefit to the current standard-of-care”

The company selected the 30 mg combination for its planned phase 3 program.

What Is the CRDF-004 Trial?

CRDF-004 (NCT06106308) is a randomized, open-label, multicenter phase 2 study evaluating onvansertib in previously untreated patients with KRAS- or NRAS-mutated metastatic colorectal cancer.

The study enrolled 110 patients in its intent-to-treat population and assessed two onvansertib doses, 20 mg and 30 mg, added to either FOLFIRI plus bevacizumab or FOLFOX plus bevacizumab. Control groups received the corresponding chemotherapy and bevacizumab combinations without onvansertib.

Its central purpose is to identify a dose and chemotherapy backbone for phase 3 development, considering response, progression-free survival, duration of response, and safety. This makes the findings relevant to regimen selection, while larger confirmatory research will be needed to establish the treatment’s benefit-risk profile.

How Does Onvansertib Work?

Onvansertib is an investigational oral inhibitor of PLK1, an enzyme that helps regulate cell division and responses to DNA damage.

The scientific rationale is to interfere with processes cancer cells use to divide and recover from chemotherapy-induced damage. Preclinical colorectal cancer studies found that PLK1 inhibition could enhance the activity of chemotherapy, supporting clinical evaluation of the combination.

This approach is particularly relevant to RAS-mutated colorectal cancer, where RAS status limits the usefulness of conventional anti-EGFR treatment strategies. Onvansertib targets PLK1 rather than directly inhibiting a specific KRAS mutation.

Earlier Research Supported First-Line Development

A previous single-arm phase 2 study, published in the Journal of Clinical Oncology, evaluated onvansertib with FOLFIRI and bevacizumab in 53 patients with previously treated KRAS-mutated metastatic colorectal cancer.

The confirmed response rate was 26.4%, and median response duration was 11.7 months. Grade 3 or 4 adverse events occurred in 62% of patients.

An exploratory, post hoc analysis found greater activity among patients who had not previously received bevacizumab. That observation helped support investigation in the first-line setting. However, the subgroup findings were hypothesis-generating and should not be interpreted as a randomized comparison or directly compared with CRDF-004 results.

What FDA Fast Track Designation Means

The FDA’s Fast Track program supports development and review of treatments intended for serious conditions with unmet medical needs.

It can provide more frequent discussions with the FDA and allow completed sections of a marketing application to be submitted through rolling review. Treatments may also qualify for Priority Review or Accelerated Approval if they meet the separate requirements for those pathways.

Fast Track designation is a development milestone, not marketing approval. For onvansertib, the next key question is whether confirmatory research can establish a meaningful and durable benefit alongside an acceptable safety profile.

Read further on OncoDaily: CRDF-004 at ASCO 2026: Onvansertib Plus Chemotherapy and Bevacizumab in 1L RAS-Mutated mCRC
Onvansertib Receives FDA Fast Track Designation in RAS-Mutated Colorectal Cancer

Nare Hovhannisyan
Fact checked by Nare Hovhannisyan MD, Medical Writer
Ani Minasaryan
Medically reviewed by Ani Minasaryan MD, KOL Intelligence Lead of BIGR, Editor at OncoDaily